|January 23, 2013|
|11:07 EDT||WLP, ESRX||Express Scripts sell-off an overreaction, says JPMorgan|
JPMorgan says shares of Express Scripts (ESRX) are trading lower after WellPoint (WLP) discussed expectations for lower enrollment in 2013. However, JPMorgan thinks lower enrollment in 2013 is already factored into current expectations for Express Scripts and views today's pullback as an overreaction.
News For ESRX;WLP From The Last 14 Days
|May 21, 2015|
|11:08 EDT||ESRX||Express Scripts management to meet with Jefferies|
Meeting to be held in New York on May 26 hosted by Jefferies.
|09:38 EDT||ESRX||Express Scripts starting to win some business, says Cleveland Research|
Cleveland Research is hearing Express Scripts won the state of South Carolina business and renewal rates remain strong and on track to achieve guidance of 94%-97%.
|May 20, 2015|
|11:51 EDT||ESRX||Express Scripts' Medco to pay $7.9M to resolve kickback allegations|
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
|10:00 EDT||ESRX||On The Fly: Analyst Initiation Summary|
Subscribe for More Information
|May 19, 2015|
|16:41 EDT||ESRX||Express Scripts initiated with a Neutral at Baird|
|May 14, 2015|
|11:08 EDT||ESRX||Express Scripts management to meet with Maxim|
Meeting to be held in St. Louis, MO on May 21 hosted by Maxim.
|May 11, 2015|
|07:40 EDT||ESRX||Focus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says|
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertex’s Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasn’t announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link